FierceBiotechOriginal article
{"a":[{"_":"Kailera’s oral GLP-1 asset sees 11% weight loss, hits goals in Chinese phase 3 obesity and diabetes trials","$":{"href":"/biotech/kaileras-oral-glp-1-asset-hits-goals-chinese-phase-3-obesity-and-diabetes-trials","hreflang":"en"}}]}
Phase 3positivePositive
AI Analysis
Summary
Kailera Therapeutics' oral GLP-1 candidate achieved primary endpoints in Phase 3 trials for obesity and diabetes in China, with 11% weight loss, positioning partner Hengrui Pharma to pursue regulatory approval.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Phase 3 trials hit primary endpoints with 11% weight loss in Chinese obesity and diabetes trials
Importance:7/10
Sentiment:
0.80
GLP-1obesitydiabetesoral formulationChinaPhase 3 positive
Related Companies
Read the original article
Published by FierceBiotech on July 7, 2026 8:44 AM